| **Study name Author, year** | **Randomization adequate?** | **Allocation concealment adequate?** | **Groups similar at baseline?** | **Eligibility criteria specified?** | **Outcome assessors masked?** | **Care provider masked?** | **Patient masked?** | **Attrition and withdrawals reported?** | **Loss to followup: differential (>10%)/high (>20%)?** | **Analyze persons in the groups in which they were randomized?** | **Quality** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *ADAPT/HPTN*Bekker 2018122, Grant, 2018123 | Yes | Yes | Yes | Yes | No | No | No | Yes | No | Yes | Fair |
| *Bangkok Tenofovir Study* Choopanya, 201397 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *FEM-PREP*Van Damme, 2012120 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| Grohskopf, 201385 | Yes, see Liu 2011 | Yes, see Liu 2011 | Race differed (greater percentage black race in placebo arm; p=0.001) | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *IAVI Kenya Study* Mutua, 201253 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *IAVI**Uganda Study* Kibengo, 201354 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *IPERGAY*Molina, 201552 | Yes | Yes | Yes (except race) | Yes | Yes | Unclear | Yes | Yes | No | Yes | Good |
| *iPrEX*Grant, 2010100 | Yes | Yes | Yes | Yes | Yes | Yes, see protocol | Yes | Yes | No | Yes | Good |
| *Partners PrEP*Baeten, 201270 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *Project PrEPare ATN 082* Hosek 201394 | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Yes | Yes | No | Yes | Fair |
| *PROUD*McCormack, 201678 | Yes | Unclear | Yes | Yes | No | No | No | Yes | No | Yes | Fair |
| *Study of TDF*Peterson, 2007117 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *TDF2*Thigpen, 2012119 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |
| *VOICE*Marrazzo, 201576 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Good |

**Abbreviations:** ADAPT/HPTN=Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking/HIV Prevention Trials Network; FEM-PrEP=Pre-Exposure Prophylaxis Trial for HIV Prevention Among African Women; IAVI=International AIDS Vaccine Initiative; IPERGAY=Intervention Préventive de l’Exposition aux Risques Avec et Pour les GAYs; iPrEx=Pre-Exposure Prophylaxis Initiative; PrEP=pre-exposure prophylaxis; PROUD=Pre-Exposure Option for Reducing HIV in the UK: Immediate or Deferred; TDF=tenofovir disoproxil fumarate; TDF2=Tenofovir Disoproxil Fumarate 2 Study; VOICE=Vaginal and Oral Interventions to Control the Epidemic.